186 related articles for article (PubMed ID: 16733671)
1. In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma.
Ritchie D; Mileshkin L; Wall D; Bartholeyns J; Thompson M; Coverdale J; Lau E; Wong J; Eu P; Hicks RJ; Prince HM
Cancer Immunol Immunother; 2007 Feb; 56(2):155-63. PubMed ID: 16733671
[TBL] [Abstract][Full Text] [Related]
2. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
3. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.
Canevari S; Stoter G; Arienti F; Bolis G; Colnaghi MI; Di Re EM; Eggermont AM; Goey SH; Gratama JW; Lamers CH
J Natl Cancer Inst; 1995 Oct; 87(19):1463-9. PubMed ID: 7674333
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of intravenous infusion of ex-vivo-activated autologous blood-derived macrophages in patients with non-small-cell lung cancer: toxicity and immunomodulatory effects.
Faradji A; Bohbot A; Schmitt-Goguel M; Roeslin N; Dumont S; Wiesel ML; Lallot C; Eber M; Bartholeyns J; Poindron P
Cancer Immunol Immunother; 1991; 33(5):319-26. PubMed ID: 1651160
[TBL] [Abstract][Full Text] [Related]
5. Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcgammaRI and the epidermal growth factor receptor.
Wallace PK; Romet-Lemonne JL; Chokri M; Kasper LH; Fanger MW; Fadul CE
Cancer Immunol Immunother; 2000 Nov; 49(9):493-503. PubMed ID: 11092616
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.
Repp R; van Ojik HH; Valerius T; Groenewegen G; Wieland G; Oetzel C; Stockmeyer B; Becker W; Eisenhut M; Steininger H; Deo YM; Blijham GH; Kalden JR; van de Winkel JG; Gramatzki M
Br J Cancer; 2003 Dec; 89(12):2234-43. PubMed ID: 14676800
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with CD64-directed immunotherapy. An overview.
Curnow RT
Cancer Immunol Immunother; 1997; 45(3-4):210-5. PubMed ID: 9435876
[TBL] [Abstract][Full Text] [Related]
8. Comparison of three different methods for radiolabelling human activated T lymphocytes.
Botti C; Negri DR; Seregni E; Ramakrishna V; Arienti F; Maffioli L; Lombardo C; Bogni A; Pascali C; Crippa F; Massaron S; Remonti F; Nerini-Molteni S; Canevari S; Bombardieri E
Eur J Nucl Med; 1997 May; 24(5):497-504. PubMed ID: 9142729
[TBL] [Abstract][Full Text] [Related]
9. Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re-targeted by a bi-specific monoclonal antibody.
Lamers CH; Bolhuis RL; Warnaar SO; Stoter G; Gratama JW
Int J Cancer; 1997 Oct; 73(2):211-9. PubMed ID: 9335445
[TBL] [Abstract][Full Text] [Related]
10. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma.
Savas B; Cole SP; Tsuruo T; Pross HF
J Clin Immunol; 1996 Nov; 16(6):348-57. PubMed ID: 8946280
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
Hercend T; Farace F; Baume D; Charpentier F; Droz JP; Triebel F; Escudier B
J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
[TBL] [Abstract][Full Text] [Related]
14. Human lymphokine-activated killer cells augment immunotherapy of human colon carcinoma xenografts with monoclonal antibody D612.
Pendurthi TK; Schlom J; Primus FJ
J Immunother (1991); 1991 Feb; 10(1):2-12. PubMed ID: 2012797
[TBL] [Abstract][Full Text] [Related]
15. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
[TBL] [Abstract][Full Text] [Related]
16. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
[TBL] [Abstract][Full Text] [Related]
17. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
[TBL] [Abstract][Full Text] [Related]
18. Increased systemic, but not regional, neopterin production following intraperitoneal administration of interleukin-2 and lack of effect of pterins upon the lymphokine-activated killer cell phenomenon.
Roberts JD; Bigelow JC; Moore AL; Belinson JL; Stewart JA; Hacker MP
J Immunother Emphasis Tumor Immunol; 1994 Jan; 15(1):53-8. PubMed ID: 8110731
[TBL] [Abstract][Full Text] [Related]
19. Specific activation of resting T cells against tumour cells by bispecific antibodies and CD28-mediated costimulation is accompanied by Th1 differentiation and recruitment of MHC-independent cytotoxicity.
Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
Clin Exp Immunol; 1997 May; 108(2):352-7. PubMed ID: 9158110
[TBL] [Abstract][Full Text] [Related]
20. Adoptive immunotherapy with bispecific antibodies: targeting through macrophages.
Chokri M; Girard A; Borrelly MC; Oleron C; Romet-Lemonne JL; Bartholeyns J
Res Immunol; 1992 Jan; 143(1):95-9. PubMed ID: 1533049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
